|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
LEADERSHIP IN FIBROSIS: Potential of Pentraxin Therapeutics
Fibrosis can affect every organ and tissue of the body and is associated with a wide variety of diseases and injuries where progressive scarring and inflammation leads to loss of tissue and organ function and ultimately results in organ failure.
Promedior’s pentraxin therapeutics provide the company with a broad-range of commercial opportunities related to the immune system, including fibrosis, inflammation and auto-immune diseases, such as:
[ back to top ]
|
|
|
|
Fibrosis is the common pathway in virtually all forms of chronic organ failure, including kidney, liver, lung and heart failure. Fibrotic organ failure affects more than 20 million people in the US alone. |
|
|
|
|
|
|
|
|
|